[바이오코리아2026] "오가노이드 '규격화'가 경쟁력"｜바이오솔루션②

BioSolution's emphasis on standardization and quality control over raw technological capability demonstrates a maturation in the biotech market where commercialization success depends on regulatory approval and reproducibility. Competitive advantage in organoid development increasingly lies not in creating cellular structures, but in mastering the rigorous validation and international standardization processes required for clinical and pharmaceutical applications.